linkedin

Resource Library

Whitepapers

Implementing Global Supply Risk Mitigation Through Multi-sourcing


 

WHITRPAPER

Implementing Global
Supply Risk Mitigation
Through Multi-sourcing
David King
Director of Drug Product Operations

Since the advent of COVID-19, all industries have faced increased business risk associated with unpredictable supply chains. Responsible for developing and manufacturing COVID-19 vaccines and treatments, the pharmaceutical industry in particular has had to rapidly overcome supply chain challenges concurrent with heightened demand. David King, our Director of Drug Product Operations discusses how CDMO partners and drug developers have embraced multi-sourcing strategy to ensure uninterrupted manufacturing and mitigate supply risks. 


 

WHITRPAPER

Implementing Global
Supply Risk Mitigation
Through Multi-sourcing
David King
Director of Drug Product Operations

Since the advent of COVID-19, all industries have faced increased business risk associated with unpredictable supply chains. Responsible for developing and manufacturing COVID-19 vaccines and treatments, the pharmaceutical industry in particular has had to rapidly overcome supply chain challenges concurrent with heightened demand. David King, our Director of Drug Product Operations discusses how CDMO partners and drug developers have embraced multi-sourcing strategy to ensure uninterrupted manufacturing and mitigate supply risks. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved